Clinical Trial Update: Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation

View source ↗

Summary

Completed prospective evaluation of palivizumab efficacy in preterm infants (29-32 weeks) with bronchial hyperreactivity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchial Hyperreactivity

Drugs mentioned

• Palivizumab (Palivizumab)

Snippet

Sponsor: Rambam Health Care Campus | Conditions: Bronchial Hyperreactivity, Infant, Premature | Status: COMPLETED